[1] SCHLEICH JM, ABDULLA T, SUMMERS R, et al. An overview of cardiac morphogenesis. Arch Cardiovasc Dis. 2013;106(11): 612-623.
[2] SRIVASTAVA D. Making or breaking the heart: from lineage determination to morphogenesis. Cell. 2006;126(6):1037-1048.
[3] ZHANG L, NOMURA-KITABAYASHI A, SULTANA N, et al. Mesodermal Nkx2.5 is necessary and sufficient for early second heart field development. Dev Biol. 2014;390(1):68-79.
[4] MEGANATHAN K, SOTIRIADOU I, NATARAJAN K, et al. Signaling molecules, transcription growth factors and other regulators revealed from in-vivo and in-vitro models for the regulation of cardiac development. Int J Cardiol. 2015;183:117-128.
[5] OLSON EN. Gene regulatory networks in the evolution and development of the heart. Science. 2006;313(5795):1922-1927.
[6] SCHOTT JJ, BENSON DW, BASSON CT, et al. Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science. 1998; 281(5373):108-111.
[7] HARVEY RP. NK-2 homeobox genes and heart development. Dev Biol. 1996;178(2):203-216.
[8] SHIOJIMA I, KOMURO I, MIZUNO T, et al. Molecular cloning and characterization of human cardiac homeobox gene CSX1. Circ Res. 1996;79(5):920-929.
[9] KASAHARA H, LEE B, SCHOTT JJ, et al. Loss of function and inhibitory effects of human CSX/NKX2.5 homeoprotein mutations associated with congenital heart disease. J Clin Invest. 2000; 106(2):299-308.
[10] AKAZAWA H, KOMURO I. Cardiac transcription factor Csx/Nkx2-5: Its role in cardiac development and diseases. Pharmacol Ther. 2005; 107(2):252-268.
[11] WATADA H, MIRMIRA RG, KALAMARAS J, et al. Intramolecular control of transcriptional activity by the NK2-specific domain in NK-2 homeodomain proteins. Proc Natl Acad Sci U S A. 2000; 97(17): 9443-9448.
[12] ELLIOTT DA, SOLLOWAY MJ, WISE N, et al. A tyrosine-rich domain within homeodomain transcription factor Nkx2-5 is an essential element in the early cardiac transcriptional regulatory machinery. Development. 2006;133(7):1311-1322.
[13] BOUVERET R, WAARDENBERG AJ, SCHONROCK N, et al. NKX2-5 mutations causative for congenital heart disease retain functionality and are directed to hundreds of targets. Elife. 2015;4.
[14] TURBAY D, WECHSLER SB, BLANCHARD KM, et al. Molecular cloning, chromosomal mapping, and characterization of the human cardiac-specific homeobox gene hCsx. Mol Med. 1996; 2(1):86-96.
[15] BRUNEAU BG. The developmental genetics of congenital heart disease. Nature. 2008;451(7181):943-948.
[16] LINTS TJ, PARSONS LM, HARTLEY L, et al. Nkx-2.5: a novel murine homeobox gene expressed in early heart progenitor cells and their myogenic descendants. Development. 1993;119(2): 419-431.
[17] SERPOOSHAN V, LIU YH, BUIKEMA JW, et al. Nkx2.5+ Cardiomyoblasts Contribute to Cardiomyogenesis in the Neonatal Heart. Sci Rep. 2017; 7(1):12590.
[18] WU SM, FUJIWARA Y, CIBULSKY SM, et al. Developmental origin of a bipotential myocardial and smooth muscle cell precursor in the mammalian heart. Cell. 2006;127(6):1137-1150.
[19] ZAMIR L, SINGH R, NATHAN E, et al. Nkx2.5 marks angioblasts that contribute to hemogenic endothelium of the endocardium and dorsal aorta. Elife. 2017;6: e20994.
[20] PAFFETT-LUGASSY N, SINGH R, NEVIS KR, et al. Heart field origin of great vessel precursors relies on nkx2.5-mediated vasculogenesis. Nat Cell Biol. 2013;15(11):1362-1369.
[21] CLARK CD, ZHANG B, LEE B, et al. Evolutionary conservation of Nkx2.5 autoregulation in the second heart field. Dev Biol. 2013; 374(1): 198-209.
[22] PRALL OW, MENON MK, SOLLOWAY MJ, et al. An Nkx2-5/ Bmp2/Smad1 negative feedback loop controls heart progenitor specification and proliferation. Cell. 2007;128(5): 947-959.
[23] COLOMBO S, DE SENA-TOMÁS C, GEORGE V, et al. Nkx genes establish second heart field cardiomyocyte progenitors at the arterial pole and pattern the venous pole through Isl1 repression. Development. 2018;145(3): dev161497.
[24] GEORGE V, COLOMBO S, TARGOFF KL. An early requirement for nkx2.5 ensures the first and second heart field ventricular identity and cardiac function into adulthood. Dev Biol. 2015;400(1):10-22.
[25] ARMIÑÁN A, GANDÍA C, BARTUAL M, et al. Cardiac differentiation is driven by NKX2.5 and GATA4 nuclear translocation in tissue-specific mesenchymal stem cells. Stem Cells Dev. 2009;18(6):907-918.
[26] RYAN T, SHELTON M, LAMBERT JP, et al. Myosin phosphatase modulates the cardiac cell fate by regulating the subcellular localization of Nkx2.5 in a Wnt/Rho-associated protein kinase-dependent pathway. Circ Res. 2013;112(2):257-266.
[27] NAKASHIMA Y, YANEZ DA, TOUMA M, et al. Nkx2-5 suppresses the proliferation of atrial myocytes and conduction system. Circ Res. 2014; 114(7):1103-1113.
[28] DORN T, GOEDEL A, LAM JT, et al. Direct nkx2-5 transcriptional repression of isl1 controls cardiomyocyte subtype identity. Stem Cells. 2015;33(4):1113-1129.
[29] RUAN Z, ZHU L, YIN Y, et al. Overexpressing NKx2.5 increases the differentiation of human umbilical cord drived mesenchymal stem cells into cardiomyocyte-like cells. Biomed Pharmacother. 2016;78:110-115.
[30] DENG B, WANG JX, HU XX, et al. Nkx2.5 enhances the efficacy of mesenchymal stem cells transplantation in treatment heart failure in rats. Life Sci. 2017;182:65-72.
[31] JAY PY, HARRIS BS, BUERGER A, et al. Function follows form: cardiac conduction system defects in Nkx2-5 mutation. Anat Rec A Discov Mol Cell Evol Biol. 2004;280(2):966-972.
[32] BRIGGS LE, TAKEDA M, CUADRA AE, et al. Perinatal loss of Nkx2-5 results in rapid conduction and contraction defects. Circ Res. 2008; 103(6):580-590.
[33] TAKEDA M, BRIGGS LE, WAKIMOTO H, et al. Slow progressive conduction and contraction defects in loss of Nkx2-5 mice after cardiomyocyte terminal differentiation. Lab Invest. 2009;89(9): 983-993.
[34] PASHMFOROUSH M, LU JT, CHEN H, et al. Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block. Cell. 2004;117(3):373-386.
[35] HARRINGTON JK, SORABELLA R, TERCEK A, et al. Nkx2.5 is essential to establish normal heart rate variability in the zebrafish embryo. Am J Physiol Regul Integr Comp Physiol. 2017;313(3): R265-R271.
[36] XIE WH, CHANG C, XU YJ, et al. Prevalence and spectrum of Nkx2.5 mutations associated with idiopathic atrial fibrillation. Clinics (Sao Paulo). 2013;68(6):777-784.
[37] PERERA JL, JOHNSON NM, JUDGE DP, et al. Novel and highly lethal NKX2.5 missense mutation in a family with sudden death and ventricular arrhythmia. Pediatr Cardiol. 2014;35(7):1206-1212.
[38] MONACO I, SANTACROCE R, CASAVECCHIA G, et al. Double de novo mutations in dilated cardiomyopathy with cardiac arrest. J Electrocardiol. 2019;53:40-43.
[39] ANDERSON DJ, KAPLAN DI, BELL KM, et al. NKX2-5 regulates human cardiomyogenesis via a HEY2 dependent transcriptional network. Nat Commun. 2018;9(1):1373.
[40] NIMURA K, YAMAMOTO M, TAKEICHI M, et al. Regulation of alternative polyadenylation by Nkx2-5 and Xrn2 during mouse heart development. Elife. 2016;5: e16030.
[41] DUPAYS L, SHANG C, WILSON R, et al. Sequential Binding of MEIS1 and NKX2-5 on the Popdc2 Gene: A Mechanism for Spatiotemporal Regulation of Enhancers during Cardiogenesis. Cell Rep. 2015;13(1): 183-195.
[42] BENSON DW, SILBERBACH GM, KAVANAUGH-MCHUGH A, et al. Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. J Clin Invest. 1999; 104(11):1567-1573.
[43] CHUNG IM, RAJAKUMAR G. Genetics of Congenital Heart Defects: The NKX2-5 Gene, a Key Player. Genes (Basel). 2016;7(2): E6.
[44] GOLDMUNTZ E, GEIGER E, BENSON DW. NKX2.5 mutations in patients with tetralogy of fallot. Circulation. 2001;104(21): 2565-2568.
[45] KÖNIG K, WILL JC, BERGER F, et al. Familial congenital heart disease, progressive atrioventricular block and the cardiac homeobox transcription factor gene NKX2.5: identification of a novel mutation. Clin Res Cardiol. 2006;95(9):499-503.
[46] OUYANG P, SAAREL E, BAI Y, et al. A de novo mutation in NKX2.5 associated with atrial septal defects, ventricular noncompaction, syncope and sudden death. Clin Chim Acta. 2011;412(1-2):170-175.
[47] QU XK, QIU XB, YUAN F, et al. A novel NKX2.5 loss-of-function mutation associated with congenital bicuspid aortic valve. Am J Cardiol. 2014; 114(12):1891-1895.
[48] BIBEN C, WEBER R, KESTEVEN S, et al. Cardiac septal and valvular dysmorphogenesis in mice heterozygous for mutations in the homeobox gene Nkx2-5. Circ Res. 2000;87(10):888-895.
[49] LIU XY, WANG J, YANG YQ, et al. Novel NKX2-5 mutations in patients with familial atrial septal defects. Pediatr Cardiol. 2011; 32(2):193-201.
[50] IKEDA Y, HIROI Y, HOSODA T, et al. Novel point mutation in the cardiac transcription factor CSX/NKX2.5 associated with congenital heart disease. Circ J. 2002;66(6):561-563.
[51] ZAKARIYAH AF, RAJGARA RF, VEINOT JP, et al. Congenital heart defect causing mutation in Nkx2.5 displays in vivo functional deficit. J Mol Cell Cardiol. 2017;105:89-98.
[52] ELLESØE SG, JOHANSEN MM, BJERRE JV, et al. Familial Atrial Septal Defect and Sudden Cardiac Death: Identification of a Novel NKX2-5 Mutation and a Review of the Literature. Congenit Heart Dis. 2016; 11(3):283-290.
[53] PABST S, WOLLNIK B, ROHMANN E, et al. A novel stop mutation truncating critical regions of the cardiac transcription factor NKX2-5 in a large family with autosomal-dominant inherited congenital heart disease. Clin Res Cardiol. 2008;97(1):39-42.
[54] HUANG W, MENG H, QIAO Y, et al. Two novel and functional DNA sequence variants within an upstream enhancer of the human NKX2-5 gene in ventricular septal defects. Gene. 2013; 524(2):152-155.
[55] WATANABE Y, BENSON DW, YANO S, et al. Two novel frameshift mutations in NKX2.5 result in novel features including visceral inversus and sinus venosus type ASD. J Med Genet. 2002;39(11):807-811.
[56] DINESH SM, KUSUMA L, SMITHA R, et al. Single-nucleotide polymorphisms of NKX2.5 found in congenital heart disease patients of Mysore, South India. Genet Test Mol Biomarkers. 2010;14(6):873-879.
[57] CAO Y, LAN W, LI Y, et al. Single nucleotide polymorphism of NKX2-5 gene with sporadic congenital heart disease in Chinese Bai population. Int J Clin Exp Pathol. 2015;8(11):14917-14924.
[58] MONZEN K, ZHU W, KASAI H, et al. Dual effects of the homeobox transcription factor Csx/Nkx2-5 on cardiomyocytes. Biochem Biophys Res Commun. 2002;298(4):493-500.
[59] TOKO H, ZHU W, TAKIMOTO E, et al. Csx/Nkx2-5 is required for homeostasis and survival of cardiac myocytes in the adult heart. J Biol Chem. 2002;277(27):24735-24743.
[60] RIAZI AM, LEE H, HSU C, et al. CSX/Nkx2.5 modulates differentiation of skeletal myoblasts and promotes differentiation into neuronal cells in vitro. J Biol Chem. 2005;280(11): 10716-10720.
[61] UDAGER AM, PRAKASH A, SAENZ DA, et al. Proper development of the outer longitudinal smooth muscle of the mouse pylorus requires Nkx2-5 and Gata3. Gastroenterology. 2014;146(1):157-165.e10.
[62] HWANG C, JANG S, CHOI DK, et al. The role of nkx2.5 in keratinocyte differentiation. Ann Dermatol. 2009;21(4):376-381.
[63] DRITSOULA A, PAPAIOANNOU I, GUERRA SG, et al. Molecular Basis for Dysregulated Activation of NKX2-5 in the Vascular Remodeling of Systemic Sclerosis. Arthritis Rheumatol. 2018;70(6):920-931.
[64] VAN ENGELEN K, MOMMERSTEEG MT, BAARS MJ, et al. The ambiguous role of NKX2-5 mutations in thyroid dysgenesis. PLoS One. 2012;7(12):e52685.
[65] PENHA RCC, BUEXM LA, RODRIGUES FR, et al. NKX2.5 is expressed in papillary thyroid carcinomas and regulates differentiation in thyroid cells. BMC Cancer. 2018;18(1):498.
[66] NAGEL S, KAUFMANN M, DREXLER HG, et al. The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). Cancer Res. 2003;63(17):5329-5334.
[67] SHIBATA K, KAJIYAMA H, YAMAMOTO E, et al. Establishment and characterization of an ovarian yolk sac tumor cell line reveals possible involvement of Nkx2.5 in tumor development. Oncology. 2008;74 (1-2):104-111.
[68] WU M, PENG S, YANG J, et al. Baf250a orchestrates an epigenetic pathway to repress the Nkx2.5-directed contractile cardiomyocyte program in the sinoatrial node. Cell Res. 2014;24(10):1201-1213.
[69] RISEBRO CA, SEARLES RG, MELVILLE AA, et al. Prox1 maintains muscle structure and growth in the developing heart. Development. 2009;136(3):495-505.
[70] RISEBRO CA, PETCHEY LK, SMART N, et al. Epistatic rescue of Nkx2.5 adult cardiac conduction disease phenotypes by prospero-related homeobox protein 1 and HDAC3. Circ Res. 2012;111(2):e19-31.
[71] SNYDER M, HUANG XY, ZHANG JJ. Stat3 directly controls the expression of Tbx5, Nkx2.5, and GATA4 and is essential for cardiomyocyte differentiation of P19CL6 cells. J Biol Chem. 2010;285(31): 23639-23646.
[72] SULTANA N, NAG K, HOSHIJIMA K, et al. Zebrafish early cardiac connexin, Cx36.7/Ecx, regulates myofibril orientation and heart morphogenesis by establishing Nkx2.5 expression. Proc Natl Acad Sci U S A. 2008;105(12):4763-4768.
[73] JODOIN R, CARRIER JC, RIVARD N, et al. G-quadruplex located in the 5’UTR of the BAG-1 mRNA affects both its cap-dependent and cap-independent translation through global secondary structure maintenance. Nucleic Acids Res. 2019;47(19):10247-10266.
[74] NIE J, JIANG M, ZHANG X, et al. Post-transcriptional Regulation of Nkx2-5 by RHAU in Heart Development. Cell Rep. 2015;13(4): 723-732.
[75] WANG J, ZHANG H, IYER D, et al. Regulation of cardiac specific nkx2.5 gene activity by small ubiquitin-like modifier. J Biol Chem. 2008; 283(34):23235-23243.
[76] TANG X, MA H, HAN L, et al. SIRT1 deacetylates the cardiac transcription factor Nkx2.5 and inhibits its transcriptional activity. Sci Rep. 2016;6:36576.
[77] COSTA MW, LEE S, FURTADO MB, et al. Complex SUMO-1 regulation of cardiac transcription factor Nkx2-5. PLoS One. 2011;6(9):e24812.
[78] RAMACHANDRA CJ, MEHTA A, WONG P, et al. ErbB4 Activated p38γ MAPK Isoform Mediates Early Cardiogenesis Through NKx2.5 in Human Pluripotent Stem Cells. Stem Cells. 2016;34(2):288-298.
[79] PRADHAN A, ZENG XI, SIDHWANI P, et al. FGF signaling enforces cardiac chamber identity in the developing ventricle. Development. 2017;144(7):1328-1338.
[80] KAY M, SOLTANI BM, AGHDAEI FH, et al. Hsa-miR-335 regulates cardiac mesoderm and progenitor cell differentiation. Stem Cell Res Ther. 2019; 10(1):191.
[81] DUROCHER D, CHARRON F, WARREN R, et al. The cardiac transcription factors Nkx2-5 and GATA-4 are mutual cofactors. EMBO J. 1997;16(18): 5687-5696.
[82] LEE Y, SHIOI T, KASAHARA H, et al. The cardiac tissue-restricted homeobox protein Csx/Nkx2.5 physically associates with the zinc finger protein GATA4 and cooperatively activates atrial natriuretic factor gene expression. Mol Cell Biol. 1998;18(6):3120-3129.
[83] KINNUNEN S, VÄLIMÄKI M, TÖLLI M, et al. Nuclear Receptor-Like Structure and Interaction of Congenital Heart Disease-Associated Factors GATA4 and NKX2-5. PLoS One. 2015;10(12):e0144145.
[84] HIROI Y, KUDOH S, MONZEN K, et al. Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation. Nat Genet. 2001;28(3):276-280.
[85] KOJIC S, NESTOROVIC A, RAKICEVIC L, et al. Cardiac transcription factor Nkx2.5 interacts with p53 and modulates its activity. Arch Biochem Biophys. 2015;569:45-53.
[86] CHEN CY, SCHWARTZ RJ. Recruitment of the tinman homolog Nkx-2.5 by serum response factor activates cardiac alpha-actin gene transcription. Mol Cell Biol. 1996;16(11):6372-6384.
[87] CAMBIER L, PLATE M, SUCOV HM, et al. Nkx2-5 regulates cardiac growth through modulation of Wnt signaling by R-spondin3. Development. 2014;141(15):2959-2971.
[88] WARREN SA, TERADA R, BRIGGS LE, et al. Differential role of Nkx2-5 in activation of the atrial natriuretic factor gene in the developing versus failing heart. Mol Cell Biol. 2011;31(22): 4633-4645.
[89] RIAZI AM, TAKEUCHI JK, HORNBERGER LK, et al. NKX2-5 regulates the expression of beta-catenin and GATA4 in ventricular myocytes. PLoS One. 2009;4(5):e5698.
[90] WANG J, JIN Y, CATTINI PA. Expression of the Cardiac Maintenance and Survival Factor FGF-16 Gene Is Regulated by Csx/Nkx2.5 and Is an Early Target of Doxorubicin Cardiotoxicity. DNA Cell Biol. 2017;36(2): 117-126.
[91] THOMAS G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol. 2002;3(10):753-766.
[92] CUI Y, HACKENMILLER R, BERG L, et al. The activity and signaling range of mature BMP-4 is regulated by sequential cleavage at two sites within the prodomain of the precursor. Genes Dev. 2001;15(21):2797-2802.
[93] CUI Y, JEAN F, THOMAS G, et al. BMP-4 is proteolytically activated by furin and/or PC6 during vertebrate embryonic development. EMBO J. 1998;17(16):4735-4743.
[94] DUPAYS L, TOWERS N, WOOD S, et al. Furin, a transcriptional target of NKX2-5, has an essential role in heart development and function. PLoS One. 2019;14(3):e0212992.
[95] PATIENT RK, MCGHEE JD. The GATA family (vertebrates and invertebrates). Curr Opin Genet Dev. 2002;12(4):416-422.
[96] CAPRIOLI A, KOYANO-NAKAGAWA N, IACOVINO M, et al. Nkx2-5 represses Gata1 gene expression and modulates the cellular fate of cardiac progenitors during embryogenesis. Circulation. 2011; 123(15): 1633-1641.
[97] CAI CL, LIANG X, SHI Y, et al. Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. Dev Cell. 2003;5(6):877-889. |